Lataa...
Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study
Melanoma of unknown primary (MUP) may have a different biology to melanoma of known primary, but clinical trials of novel therapies (e.g., immune checkpoint or BRAF/MEK inhibitors) have not reported the outcomes in this population. We therefore evaluated the overall survival (OS) among patients with...
Tallennettuna:
| Julkaisussa: | Int J Cancer |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Inc.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6900034/ https://ncbi.nlm.nih.gov/pubmed/30801710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32229 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|